Richard L. Lindstrom Md - Jun 11, 2025 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Director
Signature
/s/ Todd Anderman, Attorney-in-Fact for Richard L. Lindstrom, M.D.
Stock symbol
OCUL
Transactions as of
Jun 11, 2025
Transactions value $
$0
Form type
4
Date filed
6/13/2025, 04:24 PM
Previous filing
May 28, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LINDSTROM RICHARD L MD Director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD /s/ Todd Anderman, Attorney-in-Fact for Richard L. Lindstrom, M.D. 2025-06-13 0001242177

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +14K +10.84% $0.00 143K Jun 11, 2025 Direct F1, F2
holding OCUL Common Stock 43.6K Jun 11, 2025 By Lindstrom Family No 2 Limited Partnership F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +44K $0.00 44K Jun 11, 2025 Common Stock 44K $8.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 11, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2 Includes 43,559 shares owned indirectly by the reporting person that have previously been erroneously reported as directly owned.
F3 Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

Remarks:

Exhibit 24 - Power of Attorney